Clinical Trial Update: A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder [Phase 3]

View source ↗

Summary

Phase 3 long-term safety, tolerability and efficacy study of darifenacin in adults with overactive bladder; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Darifenacin (darifenacin)

Snippet

Sponsor: Novartis | Conditions: Overactive Bladder Syndrome | Phase 3 | Status: COMPLETED